Is compounded semaglutide as safe as Wegovy?
Compounded semaglutide from a PCAB-accredited 503A pharmacy with USP-71 sterility testing is clinically similar to brand Wegovy. The variable is the pharmacy, not the molecule. The FDA shortage exemption that legalised mass-compounding ended for most providers in mid-2025; many remaining offers are operating under specific patient-needs exceptions or grey-zone routes.
Last reviewed · Panya.health editorial
Same molecule, different pharmacy
Semaglutide is semaglutide. The active peptide in a legitimate compounded vial is the same molecule Novo Nordisk sells in Wegovy and Ozempic. The synthesis route differs (brand uses Novo's process; 503A pharmacies typically source API from FDA-registered manufacturers like AmbioPharm, Bachem, or PolyPeptide). Where compounded products legitimately differ from brand: concentration (multi-dose vials at 5 or 10 mg/mL versus brand's fixed-dose pens), excipients (citrate or phosphate buffers versus brand's specific formulation), and preservatives (multi-dose vials contain benzyl alcohol; brand pens are preservative-free).
The 2025 FDA shortage-exemption shift
From 2022 through early 2025, the FDA's drug-shortage exemption permitted 503A and 503B pharmacies to compound semaglutide to fill the supply gap. The exemption ended for semaglutide in May 2025 once Novo Nordisk's supply normalised. Many of the high-volume compounding telehealth services operating in April 2026 either (a) continue under a patient-specific clinical-need exception (allowed when brand cannot be supplied to that specific patient), (b) operate via 503B outsourcing facilities under tighter rules, or (c) operate in a grey zone the FDA has flagged but not yet enforced. The legal landscape is shifting; the clinical landscape is mostly stable.
Five questions for any compounding telehealth
Ask, in this order: Which pharmacy compounds your product, and is it PCAB-accredited? Do you have USP-71 sterility testing per lot, with documented results? Where does your API come from, and can you share the third-party Certificate of Analysis? What is the cold-chain SOP from your pharmacy to my door? And what is your protocol if I have an adverse event, including who reviews it and what gets reported to MedWatch? A telehealth that answers all five concretely is roughly equivalent to brand Wegovy on safety. One that dodges any of the five is a different risk class.
Related posts
The real differences between compounded tirzepatide from a 503A pharmacy and brand Mounjaro from Eli Lilly. Regulatory status, quality control, pricing, and when one is clearly better than the other.
US employer health plans often exclude weight-loss medication even when they cover Type 2 diabetes. Here is why the coverage gap exists, how to check your specific plan, and the legitimate workarounds...
The three GLP-1 drugs that matter in 2026: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (Lilly's triple-agonist). How they differ in mechanism, weight loss, side effe...
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.